Scalper1 News
European drug giants Sanofi (SNY) and Novo Nordisk (NVO) saw their shares fall Thursday as they issued weak guidance in the face of an increasingly competitive diabetes market. Sanofi reported Q3 earnings of 1.61 euros (90 cents) a share, up 9.5% from the year-earlier quarter and 1 cent over analysts’ consensus, according to Thomson Reuters. Sales grew 9.2% to 9.59 billion euros ($10.7 billion), missing estimates by about 150 million euros. Sanofi Scalper1 News
Scalper1 News